A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Underestimation of disease severity is a major problem confronting the successful clinical management of non-small cell lung cancer. Recent advances in molecular biological substaging may provide an opportunity to identify those patients with the most aggressive forms of the disease, but there is a continuing need for accurate markers of disease relapse and survival. In our present study, immunohistochemical analyses of a retrospective database of pathologic specimens were used to demonstratepmid:12576426 fatcat:652feextwzhvpd2pogepyaemra